Axitinib combination therapies versus sunitinib for renal cell carcinoma

被引：0
|
作者：
Stirrups, Robert
机构：
来源：
LANCET ONCOLOGY | 2019年 / 20卷 / 03期
关键词：
D O I：
10.1016/S1470-2045(19)30104-4
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
[No abstract available]
引用
下载
收藏
页码：E141 / E141
页数：1
相关论文
共 50 条
  • [1] Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma
    Motzer, Robert J.
    Penkov, Konstantin
    Haanen, John
    Rini, Brian
    Albiges, Laurence
    Campbell, Matthew T.
    Venugopal, Balaji
    Kollmannsberger, Christian
    Negrier, Sylvie
    Uemura, Motohide
    Lee, Jae L.
    Vasiliev, Aleksandr
    Miller, Wilson H., Jr.
    Gurney, Howard
    Schmidinger, Manuela
    Larkin, James
    Atkins, Michael B.
    Bedke, Jens
    Alekseev, Boris
    Wang, Jing
    Mariani, Mariangela
    Robbins, Paul B.
    Chudnovsky, Aleksander
    Fowst, Camilla
    Hariharan, Subramanian
    Huang, Bo
    di Pietro, Alessandra
    Choueiri, Toni K.
    NEW ENGLAND JOURNAL OF MEDICINE, 2019, 380 (12): : 1103 - 1115
  • [2] Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma
    Rini, Brian I.
    Plimack, Elizabeth R.
    Stus, Viktor
    Gafanov, Rustem
    Hawkins, Robert
    Nosov, Dmitry
    Pouliot, Frederic
    Alekseev, Boris
    Soulieres, Denis
    Melichar, Bohuslav
    Vynnychenko, Ihor
    Kryzhanivska, Anna
    Bondarenko, Igor
    Azevedo, Sergio J.
    Borchiellini, Delphine
    Szczylik, Cezary
    Markus, Maurice
    McDermott, Raymond S.
    Bedke, Jens
    Tartas, Sophie
    Chang, Yen-Hwa
    Tamada, Satoshi
    Shou, Qiong
    Perini, Rodolfo F.
    Chen, Mei
    Atkins, Michael B.
    Powles, Thomas
    NEW ENGLAND JOURNAL OF MEDICINE, 2019, 380 (12): : 1116 - 1127
  • [3] Axitinib versus sunitinib as first-line therapies for metastatic renal cell carcinoma: A multicenter retrospective analysis.
    Hatakeyama, Shingo
    Tanaka, Toshiaki
    Ikehata, Yoshinori
    Fujita, Naoki
    Masumori, Naoya
    Kitamura, Hiroshi
    Yoneyama, Takahiro
    Hashimoto, Yasuhiro
    Ohyama, Chikara
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
  • [4] Re: Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma
    Teh, Jiasian
    Narasimhan, Vignesh
    Schultz, Stephen
    Sathianathen, Niranjan
    Murphy, Declan G.
    EUROPEAN UROLOGY, 2019, 76 (01) : 126 - 127
  • [5] Advanced Renal Cell Carcinoma: Combination of Nivolumab and Ipilimumab versus Sunitinib
    Lorenz, Judith
    AKTUELLE UROLOGIE, 2019, 50 (02) : 136 - 136
  • [6] The outcome to axitinib or everolimus after sunitinib in metastatic renal cell carcinoma
    Iacovelli, Roberto
    Rocca, Maria Cossu
    Galli, Luca
    Sabbatini, Roberto
    De Giorgi, Ugo
    Santini, Daniele
    Facchini, Gaetano
    Mosca, Alessandra
    Atzori, Francesco
    Zucali, Paolo
    Fornarini, Giuseppe
    Massari, Francesco
    Buti, Sebastiano
    Ricotta, Riccardo
    Masini, Cristina
    Toscani, Ilaria
    Biasco, Elisa
    Guida, Annalisa
    Lolli, Cristian
    De Lisi, Delia
    Rossetti, Sabrina
    Terrone, Carlo
    Scartozzi, Mario
    Miggiano, Chiara
    Pastorino, Alessandro
    Bersanelli, Melissa
    Carlo-Stella, Giulia
    Pinto, Carmine
    Nobili, Elisabetta
    Nole, Franco
    Tortora, Giampaolo
    Porta, Camillo
    ANTI-CANCER DRUGS, 2018, 29 (07) : 705 - 709
  • [7] Sunitinib and other targeted therapies for renal cell carcinoma
    T Powles
    S Chowdhury
    R Jones
    M Mantle
    P Nathan
    A Bex
    L Lim
    T Hutson
    British Journal of Cancer, 2011, 104 : 741 - 745
  • [8] Sunitinib and other targeted therapies for renal cell carcinoma
    Powles, T.
    Chowdhury, S.
    Jones, R.
    Mantle, M.
    Nathan, P.
    Bex, A.
    Lim, L.
    Hutson, T.
    BRITISH JOURNAL OF CANCER, 2011, 104 (05) : 741 - 745
  • [9] Phase 3 study of avelumab in combination with axitinib versus sunitinib as first-line treatment for patients with advanced renal cell carcinoma (aRCC)
    Motzer, R. J.
    Choueiri, T.
    Larkin, J.
    Albiges, L.
    Haanen, J. B.
    Schmidinger, M.
    Atkins, M. B.
    Mariani, M.
    Shnaidman, M.
    Di Pietro, A.
    Rini, B. I.
    ANNALS OF ONCOLOGY, 2016, 27
  • [10] Axitinib in advanced renal cell carcinoma: Outcomes following pazopanib or sunitinib.
    Laskey, Jennifer
    Venugopal, Balaji
    Thomson, Nicola
    O'Donoghue, Roisin
    Jones, Robert J.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (02)
12345